novo nordisk new glp 1 asks FDA to prevent compounders from making GLP-1 knockoffs Novo Nordisk cuts prices as

This clears debris from the sublingual area and may improve absorption

Loureno et al

In its June 2023 final guidance, CMS stated that it will monitor whether meaningful competition continues to exist in the market by ongoing assessments of whether the manufacturer of the generic drug or biosimilar is engaging in bona fide marketing. CMS has stated this monitoring will encompass multiple activities, including whether the biosimilar is regularly and consistently available for purchase through the pharmaceutical supply chain, market data, government price reporting, and other sources

These drugs mimic GLP-1s effects to aid in weight loss and diabetes management